Peter Van Loo

Professor in cancer genomics and tumor evolution at MD Anderson Cancer Center
Visiting Group Leader at the Francis Crick Institute

[Peter Van Loo @VanLooLab]

🚀 Excited to share our latest research! We developed GRITIC, a novel method for timing genomic gains using bulk WGS data. Our findings reveal non-parsimonious evolution and increased chromosomal instability post-genome doubling in tumors. https://t.co/I2ckeoZIJ7 #cancergenomics

[Nature Cancer @NatureCancer]

NEW REVIEW ARTICLE @NatureCancer – “Aneuploidy and complex genomic rearrangements in cancer evolution” by @VanLooLab #TobyMBaker #SaraWaise #MaximeTarabichi.

Read it here👇
https://t.co/OPWDq8Am3E
https://t.co/6TVKbuHWyx

[Peter Van Loo @VanLooLab]

Exciting find in our #OralCancer study! 🧬 Brush biopsies prove promising, reflecting 90% of somatic changes vs. tissue biopsies. 🩸 Highlighting their potential in understanding tumor evolution. #CancerEvolution https://t.co/5kkXUrHyRj

[Peter Van Loo @VanLooLab]

GRITIC is now available on GitHub. It requires allele-specific copy number, SNV calls and (optionally) subclonal SNV clustering information. Try it out:
https://t.co/nNj97e7E12

[Peter Van Loo @VanLooLab]

📢Our latest preprint! We present GRITIC, a generic method to time complex copy number gains from WGS data. We apply GRITIC to 5656 tumors to paint the landscape of complex CNA evolution pan-cancer, focussing on genome-doubled primaries and mets. https://t.co/ymrXHdaLLH

[Victoria Aranda @mvicaracal]

Today, @nature and @NatureMedicine are proud to publish amazing new insights into lung cancer evolution from the #TRACERx consortium. Updated collection: https://t.co/MmOQoU47uU Great author threads👇

[Khandan Keyomarsi @kandymarsy]

World class TRIUMPH mentors are hiring post-doctoral fellows @MDAndersonNews: @JenWargoMD @swatowic @rkalluriMDPhD @TaniguchiMD @VanLooLab @tcellsrus @WenyiWang4 @AnilSoodMD @MazurLab @LiMaCancerLab @ACKoongMDPhD @skopetz @GeorgeACalin1
Apply: https://t.co/YeFVh5O0dm

[Roland Schwarz @rfschwarz]

How can we track cancer evolution using somatic copy-number alterations while considering whole-genome doubling events?
With MEDICC2, now out in Genome Biology!
https://t.co/1uhlsNOUBv
https://t.co/OX6uXVtt6i
https://t.co/F0mjcJFkpy

[The Francis Crick Institute @TheCrick]

Registration is now open for our Somatic Evolution and Tumour Microenvironment (SETM) symposium, where discussions and talks will focus on improving our understanding of cancer evolution.

📅 12 December 2022
🎟️ Free to attend online or in person

https://t.co/hufl7AIJNd

[Peter Van Loo @VanLooLab]

These signatures are the first step in cataloguing the processes that culminate in the copy number states we observe in tumors. As with mutational signatures, these studies have set a foundation for the community to build on their methods and discover CIN aetiologies. (4/4)

[Peter Van Loo @VanLooLab]

For years, we’ve looked for recurrent copy number changes in cancer but lacked a pan-cancer view of the processes that give rise to these events. We've collaborated on two @Nature studies into the mechanisms underlying aneuploidy and chromosomal instability (1/4)

[Peter Van Loo @VanLooLab]

@DrewsRM et al. deconstructed chromosomal instability in 6,335 cancers to discover 10 pan-cancer and 7 cancer-type-enriched signatures. CIN signatures associated with known aetiologies - replication stress, mis-segregation and impaired recombination: https://t.co/vW8gSCKGUn (3/4)

[Peter Van Loo @VanLooLab]

Total mRNA expression in tumor cells is an important, but so far elusive, biomarker. This elegant piece of team science establishes the mathematical relationships between copy number, purity and gene expression in tumor cells. Proud to have been part of this great team!

[Wenyi Wang @WenyiWang4]

Very excited to share our paper in Nature Biotechnology today! Huge amount of work by @ShaolongCao @sxj307 @JenniferWangMD et al! It is amazing to work with many experts across cancers. Every cancer tells its own story and our metric TmS can quantify it! https://t.co/7UiNTC745p

[Peter Van Loo @VanLooLab]

Tumor samples vary in purity and ploidy, both of which confound DNA methylation measures from bulk sequencing. We developed CAMDAC to clean up this signal. Here's our extended preprint with new insights from applying CAMDAC to TRACERx lung RRBS data: https://t.co/064PgTFt1l

[Peter Van Loo @VanLooLab]

Fantastic work linking somatic mutation rates with lifespan across mammalian species, allowing us to make sense of the lack of relationship between body size and cancer incidence.

[Alex Cagan @ATJCagan]

Incredibly excited to share our paper ‘Somatic mutation rates scale with lifespan across mammals’ now published @nature.
https://t.co/a68IkkTt33
An illustrated & updated tweetorial… [1/24]

[Peter Van Loo @VanLooLab]

We’re looking for #postdocs interested in #cancergenomics to join our lab at @MDAndersonNews – An exciting opportunity to lead large-scale studies of #tumorevolution: https://t.co/qyOX63Tlua

[CCB_VIB_KUL @vib_ccb]

We are delighted to announce Dr. Jonas Demeulemeester as a new group leader in the @VIBLifeSciences Center for Cancer Biology as of today where he will establish his Laboratory of Integrative Genomics. Welcome @zeunas at @vib_ccb!

[Peter Van Loo @VanLooLab]

🎉We’ve officially released ASCAT version 3! You can now run ASCAT on sequencing data with improved copy number calling and brand-new quality control metrics. See the full list of features and download ASCAT v3 here: https://t.co/5iEReuYOV6

[Peter Van Loo @VanLooLab]

Excited to share our new paper in @NatureGenetics! Can a mutation really hit the same place twice? We found biallelic mutations across 2,658 cancer genomes that contradict the famous infinite sites assumption and highlight the processes behind them: https://t.co/fsJkGjb23N